{"href":"https://api.simplecast.com/oembed?url=https%3A%2F%2Fneurologypodcast.simplecast.com%2Fepisodes%2Fbrain-cholesterol-in-dee-treatment-wpdixFnD","width":444,"version":"1.0","type":"rich","title":"Assess the Efficacy and Safety of Emerging Strategies That Impact Brain Cholesterol Turnover","thumbnail_width":300,"thumbnail_url":"https://image.simplecastcdn.com/images/26d7523c-7315-48a0-9da6-29d252d3ce90/8a3ad371-13a4-4f85-ba83-9c5a8d27ace7/epilepsy-am-prp6760-3000x3000.jpg","thumbnail_height":300,"provider_url":"https://simplecast.com","provider_name":"Simplecast","html":"<iframe src=\"https://player.simplecast.com/e3c35b43-3192-42c6-b6db-10910641f8b0\" height=\"200\" width=\"100%\" title=\"Assess the Efficacy and Safety of Emerging Strategies That Impact Brain Cholesterol Turnover\" frameborder=\"0\" scrolling=\"no\"></iframe>","height":200,"description":"Expert faculty discuss the treatment landscape of pediatric patients with developmental and epileptic encephalopathies, such as Lennox-Gastaut syndrome and Dravet syndrome, and the emerging role of brain cholesterol in addressing seizure frequency as shown in the ELEKTRA clinical trial of soticlestat."}